Your session is about to expire
← Back to Search
Biomarker Analysis for Prostate Cancer Radiotherapy Toxicity Prediction (GARUDA Trial)
GARUDA Trial Summary
This trial is testing a way to predict which prostate cancer patients will experience long-term genitourinary toxicity after radiation therapy, so that patients and doctors can make more informed decisions about treatment.
GARUDA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGARUDA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 29 Patients • NCT02045446GARUDA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are in the clinical trial at its peak capacity?
"Affirmative. Clinical trial records hosted on clinicaltrials.gov confirm that this medical research, which was first published on November 10th 2020, is still open for applicants. The study aims to enlist 200 participants from a single centre."
Are there still vacancies available for participation in this experiment?
"According to the clinicaltrials.gov, this medical trial is currently recruiting participants with initiation of recruitment beginning in November 2020 and most recent update taking place on December 1st 2022."
Share this study with friends
Copy Link
Messenger